Document Detail

Immunotherapeutic strategies in kidney cancer--when TKIs are not enough.
MedLine Citation:
PMID:  19546865     Owner:  NLM     Status:  MEDLINE    
FDA approval of the multitargeted, antiangiogenic tyrosine kinase inhibitors (TKIs) sunitinib and sorafenib, and the serine and threonine mammalian target of rapamycin inhibitor, temsirolimus, has revolutionized the management of metastatic clear-cell renal-cell carcinoma (CC-RCC). The inability of these targeted therapies to provide durable complete responses, however, is a serious limiting factor to their clinical usefulness. Although immunotherapeutic approaches in advanced disease are increasingly regarded as a historical treatment paradigm, we propose that a fundamental understanding of immunobiology in CC-RCC can improve the selection of patients for high-dose intravenous interleukin 2 and facilitate the development of novel immunotherapeutic strategies. In our opinion, immunotherapeutic strategies have an important place in the management of advanced CC-RCC in the era of biological targeted therapy.
Swethajit Biswas; Tim Eisen
Related Documents :
1468475 - Renal cell carcinoma with extension into the inferior vena cava: problems in diagnosis,...
7844985 - Comparison of nephrectomy and/or doxorubicin treatment in rabbit renal vx-2 carcinoma.
10080595 - Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combine...
1938215 - Metastatic renal cell carcinoma (rcc): spontaneous regression, long-term survival and l...
12222915 - Adenosquamous carcinoma of the liver: clinicopathologic features in 12 patients and rev...
25164635 - Diaphragmatic hernia in horses: 44 cases (1986-2006).
Publication Detail:
Type:  Journal Article; Review     Date:  2009-06-23
Journal Detail:
Title:  Nature reviews. Clinical oncology     Volume:  6     ISSN:  1759-4782     ISO Abbreviation:  -     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-07-31     Completed Date:  2009-10-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101500077     Medline TA:  Nat Rev Clin Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  478-87     Citation Subset:  IM    
Freeman Hospital, Newcastle upon Tyne, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / therapeutic use
Antigens, Neoplasm / analysis
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cancer Vaccines / therapeutic use
Carbonic Anhydrases / analysis
Carcinoma, Renal Cell / blood supply,  drug therapy,  immunology,  secondary*,  therapy
Clinical Trials as Topic / statistics & numerical data
Combined Modality Therapy
Cytokines / therapeutic use
Drug Delivery Systems
Immunoconjugates / therapeutic use
Infusions, Intravenous
Interferon-alpha / administration & dosage,  therapeutic use*
Interleukin-2 / administration & dosage,  therapeutic use*
Kidney Neoplasms / blood supply,  drug therapy,  immunology,  pathology,  therapy*
Meta-Analysis as Topic
Neoplasm Proteins / immunology,  physiology
Patient Selection
Protein Kinase Inhibitors / therapeutic use
T-Lymphocyte Subsets / drug effects,  immunology
Tumor Markers, Biological / analysis
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antigens, Neoplasm; 0/Antineoplastic Agents; 0/Cancer Vaccines; 0/Cytokines; 0/Immunoconjugates; 0/Interferon-alpha; 0/Interleukin-2; 0/Neoplasm Proteins; 0/Protein Kinase Inhibitors; 0/Tumor Markers, Biological; EC protein, human; EC Anhydrases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Quantitative imaging biomarkers in neuro-oncology.
Next Document:  Biomarkers of abdominal aortic aneurysm progression. Part 2: inflammation.